The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.

Autor:	Roy P; Internal Medicine, Harlem Hospital Center, New York, USA., Rafa ZI; Internal Medicine, Ibn Sina Medical College Hospital, Dhaka, BGD., Haque SN; Internal Medicine, Dhaka Medical College Hospital, Dhaka, BGD., Tasha T; Internal Medicine, Rajshahi Medical College, Rajshahi, BGD., Arko SB; Medical Intern, Dhaka Medical College Hospital, Dhaka, BGD., Agrawal H; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA., Razu MI; Otolaryngology, University of Iowa Hospitals and Clinics, Iowa City, USA., Parisapogu A; Infectious Diseases, Mayo Clinic , Rochester, USA., Maisha S; Internal Medicine, Sher-E-Bangla Medical College, Barisal, Barisal, BGD., Siddique MA; Internal Medicine, North East Medical College Hospital, Sylhet, BGD., Abbasi FK; Internal Medicine, Community Based Medical College Bangladesh, Mymensingh, BGD., Shama N; Internal Medicine, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Dhaka, BGD., Dev Nath S; Critical Care Medicine, Johns Hopkins University, Maryland, USA., Ghosh AS; Internal Medicine, Institute of Applied Health Sciences, Chittagong, BGD., Quader F; Internal Medicine, Sir Salimullah Medical College, Dhaka, BGD.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Dec 03; Vol. 14 (12), pp. e32156. Date of Electronic Publication: 2022 Dec 03 (Print Publication: 2022).
DOI:	10.7759/cureus.32156
Abstrakt:	Asthma, a chronic illness, is characterized by inflammation and airway constriction. Uncontrolled severe asthma is related to poor quality of life and increased utilization of health resources. Conventional treatments are associated with a significant amount of adverse effects. Recent years have seen the identification of various molecular effectors and signaling pathways as interesting targets for the biological therapy of severe asthma that is resistant to current therapies. Because they only target some downstream components of the inflammatory response in asthma, leaving other components unaffected, current biologic treatments only lower the exacerbation rate by 50%. If we focus on the upstream mediators of the inflammatory response in asthma, it might have a greater effect and be more efficient. Tezepelumab is a human monoclonal IgG2 antibody that specifically binds to thymic stromal lymphopoietin (TSLP) at the level of its TSLPR (thymic stromal lymphopoietin receptor) binding site, inhibiting the interaction between human TSLP and TSLPR. It is being used to treat the cytokines on the respiratory epithelial layer known as "alarmins." It is the only biologic drug available for treating severe uncontrolled asthma, despite limitations in biomarker and phenotype. In light of recent developments, the lack of knowledge on tezepelumab prompts us to publish a comprehensive systematic review. We discovered that regardless of blood eosinophil level and fractional exhaled nitric oxide levels, tezepelumab dramatically lowers asthma exacerbation in patients with severe uncontrolled asthma when compared to placebo. Tezepelumab also lessens patients' demand for healthcare resources while improving clinical indicators of lung function, health-related quality of life, and asthma management in patients. Tezepelumab plays a role in enhancing pre-bronchodilator FEV1 and lowering blood eosinophil count and fractional exhaled nitric oxide in patients with or without chronic allergies (FeNO). There have been no reports of fatalities or severe adverse events connected to tezepelumab. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Roy et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu